← Eichor
Condition: Pik3Ca Related Overgrowth Spectrum Pros Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Pik3Ca Related Overgrowth Spectrum Pros

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Patients With PIK3CA-r
Phase 1/Phase 2 · 15 location(s) · Haihe Biopharma Co., Ltd. · NCT06975618A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spe
Phase 2 · 34 location(s) · Relay Therapeutics, Inc. · NCT06789913EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediat
Phase 2 · 35 location(s) · Novartis Pharmaceuticals · NCT06997588
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.